0001104659-22-082024.txt : 20220722 0001104659-22-082024.hdr.sgml : 20220722 20220722163348 ACCESSION NUMBER: 0001104659-22-082024 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220720 FILED AS OF DATE: 20220722 DATE AS OF CHANGE: 20220722 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Power Sean A CENTRAL INDEX KEY: 0001538845 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32639 FILM NUMBER: 221100301 MAIL ADDRESS: STREET 1: 787 SEVENTH AVENUE, 48TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TG THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001001316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 363898269 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: (212) 554-4484 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030310 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960703 4 1 tm2221660-6_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-07-20 0 0001001316 TG THERAPEUTICS, INC. TGTX 0001538845 Power Sean A 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014 0 1 0 0 Chief Financial Officer Common Stock 2022-07-20 4 A 0 75000 0 A 643483 D Employee Stock Option (right to buy) 7.00 2022-07-20 4 A 0 200000 0 A 2027-07-20 Common Stock, par value $0.001 200000 200000 D Reflects a grant of restricted shares, of which 1/3 will vest on 1/1/2023, 1/3 will vest upon U.S. Food and Drug Administration approval of ublituximab as a treatment for patients with relapsing forms of multiple sclerosis, and 1/3 will vest upon approval by the European Medicines Agency of ublituximab. Includes shares of restricted Common Stock, which vest over various time periods. Reflects a grant of options relating to 2021 service and performance, of which 1/2 will vest on 1/1/2024 and 1/2 will vest upon U.S. Food and Drug Administration approval of ublituximab as a treatment for patients with relapsing forms of multiple sclerosis. /s/ Sean A. Power 2022-07-22